<DOC>
	<DOCNO>NCT02230878</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetic ( study way drug enters leave blood tissue time ) , dose-proportionality , accumulation , urinary excretion , pharmacodynamics ( study drug act body ) sedative effect JNJ-42847922 healthy male female participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics JNJ-42847922 Healthy Participants</brief_title>
	<detailed_description>This Phase 1 , double blind ( medical research study neither researcher participant know treatment participant receive ) , randomize ( study drug assign chance ) , placebo control , multiple ascend dose study . The study consist 3 part : Screening period ( Days -21 -2 ) , Double-blind treatment period ( Day -1 Day 11 ) , Follow-up period ( within 7 14 day last dose administration ) . In double blind treatment period , participant randomly assign 5 , 10 , 20 , 40 milligram ( mg ) placebo . Number participant clinically relevant change ( adverse event [ AEs ] , laboratory result , electrocardiogram [ ECG ] , Vital sign , Physical neurological , sedation &amp; concentration ) columbia suicide severity rating ( CSSR ) scale evaluate primary outcome measure . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Women child bear potential due either tubal ligation hysterectomy postmenopausal ( spontaneous menses least 2 year Body Mass Index ( BMI ) 18 30 kilogram per meter square ( kg/m^2 ) inclusive ( BMI=weight/height^2 ) Participants must healthy / medically stable basis clinical laboratory test perform screen . If result serum chemistry panel , hematology , urinalysis outside normal reference range , retesting abnormal lab value ( ) may lead exclusion allow screen phase Nonsmokers ( smoke 6 month prior screen ) Participant must willing able adhere prohibition restriction specify protocol Clinically significant abnormal value hematology , serum chemistry urinalysis screen admission Clinically significant abnormal physical neurological examination , vital sign 12lead electrocardiogram ( ECG ) screen admission History current significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematological disease , lipid abnormality , bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , Parkinson 's disease , infection , illness Investigator considers exclude participant Serology positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibodies human immunodeficiency virus ( HIV ) antibodies Subjects relevant history suicide attempt suicidal behavior . Any recent suicidal ideation within last 6 month ( level 4 5 ) , significant risk commit suicide , judge investigator use columbia suicide severity rating score ( CSSRS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>JNJ-42847922</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Healthy</keyword>
	<keyword>Placebo</keyword>
</DOC>